Tezepelumab was linked to significantly reduced nasal polyp size and nasal congestion vs placebo in adults with severe CRSwNP.

The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with ...

AZ is hoping that Fasenra (benralizumab) could join rival drugs from Sanofi/Regeneron and GlaxoSmithKline as approved therapies for chronic rhinosinusitis with nasal polyps (CRSwNP) that have been ...

Simultaneously, the three regulators are also reviewing a second potential indication for depemokimab as an add-on therapy for chronic rhinosinusitis with nasal polyps (CRSwNP). GSK has said ...

Please provide your email address to receive an email when new articles are posted on . The need for systemic corticosteroids fell by 88%, and the need for surgery fell by 98%. Nasal polyp and ...

These quiz questions about chronic rhinosinusitis with nasal polyps (CRSwNP) are derived from current literature. Are you up to date? At the end of the quiz, compare your score with those of your ...

(RTTNews) - GSK plc (GSK.L, GSK) announced that Depemokimab demonstrated clinically meaningful and statistically significant improvements for patients with chronic rhinosinusitis with nasal polyps ...

Chronic sinusitis with nasal polyps (CRSwNP) accounts for 20 to 33 percent of these cases. Even after surgical treatment, the recurrence rate of CRSwNP remains high, ranging from 20 to 60 percent ...

Several possible mechanisms have been proposed, including microbes (bacteria, fungi, viruses), biofilm formation, staphylococcal superantigen (most often associated with CRSwNP), osteitis and ...

Corticosteroid Reduction. Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of OMLYCLO therapy for asthma or CRSwNP. Eosinophilic Conditions. Be alert to eosinophilia, ...

Kaivan Khavandi, SVP and global head, respiratory, immunology & inflammation R&D, GSK, said: “Simultaneous regulatory submissions for two indications highlight our confidence in depemokimab to help ...